Niraparib + Dostarlimab for Brain Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, you must not be receiving other interventional anticancer treatments at the same time. It's best to discuss your specific medications with the trial team.
How is the drug combination of Niraparib and Dostarlimab unique for brain cancer treatment?
The combination of Niraparib and Dostarlimab is unique because it targets cancer cells by exploiting their DNA repair weaknesses and enhancing the immune system's ability to fight cancer. Niraparib, a PARP inhibitor, increases DNA damage in cancer cells, while Dostarlimab, an immune checkpoint inhibitor, helps the immune system recognize and attack these damaged cells, offering a novel approach compared to traditional treatments.12345
What data supports the effectiveness of the drug combination Niraparib and Dostarlimab for brain cancer?
Who Is on the Research Team?
Timothy Yap
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
Adults (18+) with advanced cancers that have spread to the brain, including specific types such as BRCA1/2m cancer and various lung and breast cancers. Participants must have had previous treatment, possess measurable brain metastasis not requiring immediate intervention or steroids, and adequate organ function. They cannot be pregnant or breastfeeding and must agree to contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive niraparib and dostarlimab to assess intracranial objective response rate and systemic antitumor activity
Follow-up
Participants are monitored for safety, tolerability, and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Dostarlimab
- Niraparib
Dostarlimab is already approved in European Union, United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor